Details of Drug-Drug Interaction
| Drug General Information (ID: DDINK0FABJ) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Chloroquine | Drug Info | Lumefantrine | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antimalarial Agents | Antimalarial Agents | |||||||
| Structure | |||||||||
| Mechanism of Chloroquine-Lumefantrine Interaction (Severity Level: Major) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Chloroquine | Lumefantrine | |||||||
| Mechanism | Prolong QT interval | Prolong QT interval | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | QT interval | ||||||||
| Factor Description | Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should be avoided. Moreover, artemether-lumefantrine should generally not be used in combination with other antimalarial agents due to limited safety data. Caution and close monitoring of the ECG are advised when QT-prolonging antimalarial agents are used following treatment with artemether-lumefantrine because of the long elimination half-life of lumefantrine (3 to 6 days). Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. | ||||||||